High Hampton Holdings Corp Share Price Canadian Securities Exchange
Equities
CA42966X3094
Pharmaceuticals
Sales 2022 | - | Sales 2023 | - | Capitalization | 6L 4L 3.44Cr |
---|---|---|---|---|---|
Net income 2022 | - 0 0 | Net income 2023 | - 0 0 | EV / Sales 2022 | - |
Net cash position 2022 | 8L 6L 5.14Cr | Net cash position 2023 | 7L 5L 4.22Cr | EV / Sales 2023 | - |
P/E ratio 2022 |
22.9
x | P/E ratio 2023 |
-8.18
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 79.53% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Dubeau
CEO | Chief Executive Officer | - | 26/23/26 |
Director of Finance/CFO | 53 | 19/23/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director of Finance/CFO | 53 | 19/23/19 | |
Robert Dubeau
CEO | Chief Executive Officer | - | 26/23/26 |
Anderson Shannon
BRD | Director/Board Member | - | 19/23/19 |
1st Jan change | Capi. | |
---|---|---|
+29.98% | 68TCr | |
+30.34% | 57TCr | |
-3.52% | 36TCr | |
+18.59% | 33TCr | |
+4.07% | 28TCr | |
+16.21% | 24TCr | |
+9.66% | 21TCr | |
-6.83% | 20TCr | |
+7.09% | 17TCr |